Wall Street brokerages predict that Vericel Corp (NASDAQ:VCEL) will post sales of $39.30 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Vericel’s earnings. The highest sales estimate is $39.60 million and the lowest is $38.88 million. Vericel reported sales of $31.34 million in the same quarter last year, which would indicate a positive year over year growth rate of 25.4%. The firm is expected to report its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Vericel will report full year sales of $117.74 million for the current financial year, with estimates ranging from $117.34 million to $118.00 million. For the next year, analysts anticipate that the firm will report sales of $154.57 million, with estimates ranging from $147.71 million to $165.21 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Vericel.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.09. Vericel had a positive return on equity of 3.66% and a negative net margin of 12.68%. The company had revenue of $30.50 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the company posted ($0.02) EPS. The business’s revenue for the quarter was up 35.6% compared to the same quarter last year.
In other news, COO Michael Halpin sold 15,047 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.53, for a total transaction of $278,820.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Dominick Colangelo sold 58,125 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total value of $864,900.00. The disclosure for this sale can be found here. Corporate insiders own 4.50% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC increased its holdings in Vericel by 5.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 21,605 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 1,080 shares in the last quarter. SG Capital Management LLC acquired a new stake in Vericel in the 2nd quarter valued at $12,907,000. Virginia Retirement Systems ET AL increased its holdings in Vericel by 10.3% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 13,900 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 1,300 shares in the last quarter. Redwood Investments LLC acquired a new stake in Vericel in the 2nd quarter valued at $15,775,000. Finally, Boston Advisors LLC increased its holdings in Vericel by 18.4% in the 2nd quarter. Boston Advisors LLC now owns 46,840 shares of the biotechnology company’s stock valued at $885,000 after purchasing an additional 7,277 shares in the last quarter. Institutional investors and hedge funds own 86.86% of the company’s stock.
Shares of Vericel stock traded down $0.14 during trading hours on Tuesday, reaching $18.66. 145,471 shares of the company’s stock were exchanged, compared to its average volume of 528,084. Vericel has a 52-week low of $13.40 and a 52-week high of $21.00. The firm has a market capitalization of $840.26 million, a price-to-earnings ratio of -133.29 and a beta of 2.66. The company has a fifty day moving average of $17.03 and a 200-day moving average of $17.01. The company has a current ratio of 6.93, a quick ratio of 6.48 and a debt-to-equity ratio of 0.26.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Read More: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.